, abiraterone, Enzalutamide, oestrogens, ketoconazole, and steroids along with supportive care must accompany treatment."
Informed consent for continuation of tamoxifen therapy and additional LHRH agonist
therapy was received.
Subjects receiving LHRH agonist
therapy complained of a plethora of symptoms.
It is the only LHRH agonist
available via subcutaneous injection with the innovative, controlled release ATRIGEL Delivery System.
Characteristics of luteinizing hormones (LH) and testosterone secretion, pituitary responses to LH-releasing hormone (LHRH), and reproductive function in young bulls receiving the LHRH agonist
deslorelin: effect of castration on LH responses to LHRH.
Combination therapy with flutamide and castration (LHRH agonist
or orchiectomy) in advance prostate cancer: a marked improvement in response and survival.
Pubertenin ilerlemesini yavaslatmak icin kullanilan LHRH agonist
veya aromataz tedavisi buyume icin gerekli zamani kazandirabilir (17,18); ancak bu tedavilerin etkinliginin degerlendirilebilmesi icin daha fazla sayida kontrollu calismaya ihtiyac vardir.
Key products include Ferrlecit, an intravenous iron for use in the dialysis setting; Trelstar, an LHRH agonist
for treating advanced prostate cancer; Androderm, a transdermal patch for testosterone replacement therapy in men; and Oxytrol, a transdermal patch for treating overactive bladders.
It is not possible to assign menopausal status to women receiving an LHRH agonist
or antagonist, the guidelines state.
Medroxyprogesterone acetate is not an antiandrogen per se but is, rather, a progestational agent that reduces testosterone levels indirectly Leuprolide acetate, an LHRH agonist
, has a comparable effect and has been effective in patients who did not respond to medroxyprogesterone acetate and other agents.
An LHRH agonist
is made in the laboratory; it is like LHRH but has a different effect on the body's functions.
In the Quebec population-based series of men undergoing LHRH agonist
therapy with curative radiation therapy, (24) multivariate analysis adjusting for clinical stage, pretreatment PSA, Gleason score, age, and smoking did not reveal an association between testosterone breakthrough and either biochemical failure or survival; however, subgroup analysis showed a trend toward inferior five-year biochemical failure in those with testosterone breakthroughs of greater than 1.7 nmol/L vs.